The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Drugs for Herpes Labialis (Oral Herpes) Market Research Report 2024
Synopsis
Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
The global Drugs for Herpes Labialis (Oral Herpes) market was valued at US$ 2458 million in 2023 and is anticipated to reach US$ 3449.3 million by 2030, witnessing a CAGR of 4.9% during the forecast period 2024-2030.
Global Drugs for Herpes Labialis (Oral Herpes) key players include GSK, Novartis, Teva, Mylan, Cadila, etc. Global top five manufacturers hold a share about 55%. North America is the largest market, with a share about 35%, followed by Europe, with a share about 30 percent. In terms of product, Rx Drugs is the largest segment, with a share about 90%. And in terms of application, the largest application is Oral, followed by External Use, and Injection, etc.
This report aims to provide a comprehensive presentation of the global market for Drugs for Herpes Labialis (Oral Herpes), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Herpes Labialis (Oral Herpes).
Report Scope
The Drugs for Herpes Labialis (Oral Herpes) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Herpes Labialis (Oral Herpes) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Herpes Labialis (Oral Herpes) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun
Hikma
Haiwang
Carmex
Cipher
Segment by Type
Aciclovir
Valacyclovir
Famciclovir
Docosanol
Other
Segment by Application
External Use
Oral
Injection
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Herpes Labialis (Oral Herpes) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2–3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.
The global Drugs for Herpes Labialis (Oral Herpes) market was valued at US$ 2458 million in 2023 and is anticipated to reach US$ 3449.3 million by 2030, witnessing a CAGR of 4.9% during the forecast period 2024-2030.
Global Drugs for Herpes Labialis (Oral Herpes) key players include GSK, Novartis, Teva, Mylan, Cadila, etc. Global top five manufacturers hold a share about 55%. North America is the largest market, with a share about 35%, followed by Europe, with a share about 30 percent. In terms of product, Rx Drugs is the largest segment, with a share about 90%. And in terms of application, the largest application is Oral, followed by External Use, and Injection, etc.
This report aims to provide a comprehensive presentation of the global market for Drugs for Herpes Labialis (Oral Herpes), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Herpes Labialis (Oral Herpes).
Report Scope
The Drugs for Herpes Labialis (Oral Herpes) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Herpes Labialis (Oral Herpes) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Drugs for Herpes Labialis (Oral Herpes) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun
Hikma
Haiwang
Carmex
Cipher
Segment by Type
Aciclovir
Valacyclovir
Famciclovir
Docosanol
Other
Segment by Application
External Use
Oral
Injection
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Drugs for Herpes Labialis (Oral Herpes) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Aciclovir
1.2.3 Valacyclovir
1.2.4 Famciclovir
1.2.5 Docosanol
1.2.6 Other
1.3 Market by Application
1.3.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 External Use
1.3.3 Oral
1.3.4 Injection
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Perspective (2019-2030)
2.2 Drugs for Herpes Labialis (Oral Herpes) Growth Trends by Region
2.2.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Drugs for Herpes Labialis (Oral Herpes) Historic Market Size by Region (2019-2024)
2.2.3 Drugs for Herpes Labialis (Oral Herpes) Forecasted Market Size by Region (2025-2030)
2.3 Drugs for Herpes Labialis (Oral Herpes) Market Dynamics
2.3.1 Drugs for Herpes Labialis (Oral Herpes) Industry Trends
2.3.2 Drugs for Herpes Labialis (Oral Herpes) Market Drivers
2.3.3 Drugs for Herpes Labialis (Oral Herpes) Market Challenges
2.3.4 Drugs for Herpes Labialis (Oral Herpes) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Herpes Labialis (Oral Herpes) Players by Revenue
3.1.1 Global Top Drugs for Herpes Labialis (Oral Herpes) Players by Revenue (2019-2024)
3.1.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Players (2019-2024)
3.2 Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for Herpes Labialis (Oral Herpes) Revenue
3.4 Global Drugs for Herpes Labialis (Oral Herpes) Market Concentration Ratio
3.4.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Herpes Labialis (Oral Herpes) Revenue in 2023
3.5 Drugs for Herpes Labialis (Oral Herpes) Key Players Head office and Area Served
3.6 Key Players Drugs for Herpes Labialis (Oral Herpes) Product Solution and Service
3.7 Date of Enter into Drugs for Herpes Labialis (Oral Herpes) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Herpes Labialis (Oral Herpes) Breakdown Data by Type
4.1 Global Drugs for Herpes Labialis (Oral Herpes) Historic Market Size by Type (2019-2024)
4.2 Global Drugs for Herpes Labialis (Oral Herpes) Forecasted Market Size by Type (2025-2030)
5 Drugs for Herpes Labialis (Oral Herpes) Breakdown Data by Application
5.1 Global Drugs for Herpes Labialis (Oral Herpes) Historic Market Size by Application (2019-2024)
5.2 Global Drugs for Herpes Labialis (Oral Herpes) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Drugs for Herpes Labialis (Oral Herpes) Market Size (2019-2030)
6.2 North America Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2019-2024)
6.4 North America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size (2019-2030)
7.2 Europe Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2019-2024)
7.4 Europe Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size (2019-2030)
8.2 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2019-2024)
8.4 Asia-Pacific Drugs for Herpes Labialis (Oral Herpes) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size (2019-2030)
9.2 Latin America Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2019-2024)
9.4 Latin America Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size (2019-2030)
10.2 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2019-2024)
10.4 Middle East & Africa Drugs for Herpes Labialis (Oral Herpes) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 GSK
11.1.1 GSK Company Detail
11.1.2 GSK Business Overview
11.1.3 GSK Drugs for Herpes Labialis (Oral Herpes) Introduction
11.1.4 GSK Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.1.5 GSK Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Drugs for Herpes Labialis (Oral Herpes) Introduction
11.2.4 Novartis Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Teva
11.3.1 Teva Company Detail
11.3.2 Teva Business Overview
11.3.3 Teva Drugs for Herpes Labialis (Oral Herpes) Introduction
11.3.4 Teva Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.3.5 Teva Recent Development
11.4 Mylan
11.4.1 Mylan Company Detail
11.4.2 Mylan Business Overview
11.4.3 Mylan Drugs for Herpes Labialis (Oral Herpes) Introduction
11.4.4 Mylan Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.4.5 Mylan Recent Development
11.5 Cadila
11.5.1 Cadila Company Detail
11.5.2 Cadila Business Overview
11.5.3 Cadila Drugs for Herpes Labialis (Oral Herpes) Introduction
11.5.4 Cadila Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.5.5 Cadila Recent Development
11.6 Apotex
11.6.1 Apotex Company Detail
11.6.2 Apotex Business Overview
11.6.3 Apotex Drugs for Herpes Labialis (Oral Herpes) Introduction
11.6.4 Apotex Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.6.5 Apotex Recent Development
11.7 Daewoong Pharmaceutical
11.7.1 Daewoong Pharmaceutical Company Detail
11.7.2 Daewoong Pharmaceutical Business Overview
11.7.3 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Introduction
11.7.4 Daewoong Pharmaceutical Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.7.5 Daewoong Pharmaceutical Recent Development
11.8 Livzon
11.8.1 Livzon Company Detail
11.8.2 Livzon Business Overview
11.8.3 Livzon Drugs for Herpes Labialis (Oral Herpes) Introduction
11.8.4 Livzon Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.8.5 Livzon Recent Development
11.9 Luoxin
11.9.1 Luoxin Company Detail
11.9.2 Luoxin Business Overview
11.9.3 Luoxin Drugs for Herpes Labialis (Oral Herpes) Introduction
11.9.4 Luoxin Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.9.5 Luoxin Recent Development
11.10 Med shine
11.10.1 Med shine Company Detail
11.10.2 Med shine Business Overview
11.10.3 Med shine Drugs for Herpes Labialis (Oral Herpes) Introduction
11.10.4 Med shine Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.10.5 Med shine Recent Development
11.11 Bayer (Campho Phenique)
11.11.1 Bayer (Campho Phenique) Company Detail
11.11.2 Bayer (Campho Phenique) Business Overview
11.11.3 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Introduction
11.11.4 Bayer (Campho Phenique) Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.11.5 Bayer (Campho Phenique) Recent Development
11.12 Blistex
11.12.1 Blistex Company Detail
11.12.2 Blistex Business Overview
11.12.3 Blistex Drugs for Herpes Labialis (Oral Herpes) Introduction
11.12.4 Blistex Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.12.5 Blistex Recent Development
11.13 Kelun
11.13.1 Kelun Company Detail
11.13.2 Kelun Business Overview
11.13.3 Kelun Drugs for Herpes Labialis (Oral Herpes) Introduction
11.13.4 Kelun Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.13.5 Kelun Recent Development
11.14 Hikma
11.14.1 Hikma Company Detail
11.14.2 Hikma Business Overview
11.14.3 Hikma Drugs for Herpes Labialis (Oral Herpes) Introduction
11.14.4 Hikma Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.14.5 Hikma Recent Development
11.15 Haiwang
11.15.1 Haiwang Company Detail
11.15.2 Haiwang Business Overview
11.15.3 Haiwang Drugs for Herpes Labialis (Oral Herpes) Introduction
11.15.4 Haiwang Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.15.5 Haiwang Recent Development
11.16 Carmex
11.16.1 Carmex Company Detail
11.16.2 Carmex Business Overview
11.16.3 Carmex Drugs for Herpes Labialis (Oral Herpes) Introduction
11.16.4 Carmex Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.16.5 Carmex Recent Development
11.17 Cipher
11.17.1 Cipher Company Detail
11.17.2 Cipher Business Overview
11.17.3 Cipher Drugs for Herpes Labialis (Oral Herpes) Introduction
11.17.4 Cipher Revenue in Drugs for Herpes Labialis (Oral Herpes) Business (2019-2024)
11.17.5 Cipher Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
